N

NeuBase Therapeutics Inc
F:O7PA

Watchlist Manager
NeuBase Therapeutics Inc
F:O7PA
Watchlist
Price: 0.159 EUR -3.64% Market Closed
Market Cap: €5.4m

NeuBase Therapeutics Inc
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

NeuBase Therapeutics Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
N
NeuBase Therapeutics Inc
F:O7PA
Non-Reccuring Items
-$1.9m
CAGR 3-Years
N/A
CAGR 5-Years
17%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Non-Reccuring Items
-$10.7B
CAGR 3-Years
-72%
CAGR 5-Years
-60%
CAGR 10-Years
-27%
Gilead Sciences Inc
NASDAQ:GILD
Non-Reccuring Items
-$843m
CAGR 3-Years
38%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Non-Reccuring Items
-$3.2B
CAGR 3-Years
-87%
CAGR 5-Years
N/A
CAGR 10-Years
-35%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Non-Reccuring Items
-$543m
CAGR 3-Years
-74%
CAGR 5-Years
N/A
CAGR 10-Years
-60%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Non-Reccuring Items
-$245.5m
CAGR 3-Years
26%
CAGR 5-Years
-10%
CAGR 10-Years
-20%
No Stocks Found

NeuBase Therapeutics Inc
Glance View

Market Cap
5.4m EUR
Industry
Biotechnology

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.

O7PA Intrinsic Value
Not Available
N

See Also

What is NeuBase Therapeutics Inc's Non-Reccuring Items?
Non-Reccuring Items
-1.9m USD

Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Non-Reccuring Items amounts to -1.9m USD.

What is NeuBase Therapeutics Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 5Y
17%

Back to Top